Dyslipidemia: The untreated metabolic dysfunction in people with type 2 diabetes in Latin America. ARETAEUS study outcomes

• Published in: Journal of clinical & translational endocrinology 2019-03, Vol.15, p.76-80
• Main Authors: José Gagliardino, Juan, Arechavaleta, Rosario, Goldberg Eliaschewitz, Freddy, Iglay, Kristy, Brodovicz, Kimberly, Gonzalez, Claudio D, Yu, Shengsheng, Ravi Shankar, R, Heisel, Olaf, Keown, Paul, Tunceli, Kaan
• Format: Article
• Language: English
• Subjects: Antihyperglycemic agent; Clinical inertia; Dyslipidemia; Endocrinology and Metabolism; Research Paper; Statin; Treatment initiation; Type 2 diabetes
• ISSN: 2214-6237; 2214-6237
• DOI: 10.1016/j.jcte.2019.01.002

AbstractObjectiveTo assess oral antihyperglycemic agents (OAHA) and/or statin treatment initiation in patients with type 2 diabetes (T2D) and time from diagnosis to both types of treatment initiation and intensification. Research design and methodsWe reviewed 662 retrospective medical records of patients with T2D diagnosed by 31 general practitioner or specialist sites across Mexico, Argentina, and Brazil. Demographic and clinical information was abstracted from patients’ medical records and summarized using descriptive statistics. Between-group differences were assessed with Student’s t-test for continuous variables and Fisher’s exact test for categorical variables. The starting time of each therapy (OAHA and statins, separately) was assessed using Kaplan-Meier estimates. ResultsAt diagnosis, patients’ mean age was 53 years; 44% had hypertension, 42% were obese, and 23% had dyslipidemia. During the 2-year follow-up, 95% of patients received OAHAs but only 29% of those eligible for statins received this prescription. Mean ± SD and median (Q1, Q3) time to first OAHA was 59 ± 141 days and 1 (1, 31) day, respectively, and 230 ± 232 days and 132 (30, 406) days, respectively, for a statin. During follow-up, 51–53% of patients with HbA1c/FPG values above target did not intensify hyperglycemia treatment. ConclusionDyslipidemia treatment in patients with T2D was delayed despite its known deleterious effect on atherosclerosis development and β-cell mass/function. Anti-hyperglycemic treatment was not intensified when targets were not attained. This prescriptive inertia needs to be corrected because attainment of HbA1c treatment goals becomes more difficult, favoring the development of diabetes complications.